The failure of immunosuppression withdrawal: Patient benefit is not detectable, inducible, or reproducible

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Porrett, Paige ^a   Shaked, Abraham ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MORBIDITY; PATIENT CARE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT FAILURE; TREATMENT OUTCOME; GRAFT REJECTION; IMMUNOLOGY; MORTALITY; WITHDRAWAL SYNDROME;

IMMUNOSUPPRESSIVE AGENT;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MORBIDITY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT FAILURE;

EID: 84857182612     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22377     Document Type: Article

References (14)

1. Reyes J, Zeevi A, Ramos H, Tzakis A, Todo S, Demetris AJ, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25: 3315-3319.
2. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009;50: 1247-1257.
3. Girlanda R, Rela M, Williams R, O'Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005;37: 1708-1709.
4. Pons JA, Yélamos J, Ramírez P, Oliver-Bonet M, Sánchez A, Rodríguez-Gago M, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003;75: 1045-1047.
5. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008;20: 43-47.
6. Tryphonopoulos P, Ruiz P, Weppler D, Nishida S, Levi DM, Moon J, et al. Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation 2010;90: 1556-1561.
7. Wieland E, Olbricht CJ, Süsal C, Gurragchaa P, Böhler T, Israeli M, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010;32: 560-572.
8. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349: 931-940.
9. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009;22: 49-60.
10. Assy N, Adams PC, Myers P, Simon V, Ghent CN. A randomized controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 2007;56: 304-306.
11. Pons JA, Ramírez P, Revilla-Nuin B, Pascual D, Baroja- Mazo A, Robles R, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009;23: 329-336.
12. Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl Int 2009;22: 2-19.
13. Klupp J, Pfitzmann R, Langrehr JM, Neuhaus P. Indications of mycophenolate mofetil in liver transplantation. Transplantation 2005;80(suppl): S142-S146.
14. Shaked A, Feng S, Punch J, Reyes J, Levitsky J, Klintmalm G, et al. Lessons learned from the ITN030ST immunosuppression withdrawal (ISW) trial in liver transplant recipients [abstract]. Liver Transpl 2011;17(suppl 1): S84